Platform diagnostics companies that dominate a primary indication (prenatal, rare disease) and build scale tend to expand the same core platform technology into oncology as a second S-curve. The oncology expansion starts very small (<10% of revenue) but typically grows 5-10x faster than the primary segment. The market systematically undervalues this because the absolute revenue is tiny at the time — but oncology TAM is 3-5x larger than the primary indication, and the company already owns distribution infrastructure and platform technology with no rebuild cost.
When a platform diagnostics company reports an explosively growing oncology segment at <10% of revenue, do not weight it on absolute revenue. Weight it on: (a) TAM leverage — oncology typically 3-5x the primary indication TAM, (b) growth rate — 5-10x faster than primary, (c) platform reuse — marginal cost of adding tests is low once core technology is proven, and (d) distribution leverage — existing provider relationships accelerate oncology adoption. The market typically values the primary segment correctly and treats the early oncology contribution as noise. The valuation re-rating happens when oncology crosses ~15% of revenue — that's the visibility threshold for buy-side models. Analysts anchored to current revenue mix will underestimate forward compounding.